| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy | PDUFA | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
PDUFA Date example | KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy | PDUFA | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
PDUFA Date example | KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy | PDUFA | — | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Merck & Company, Inc.$125.02
-3.47 (-2.7%)
A 93Pipeline Score Fair Value Pharma · Commercial
Market Cap
302.33 B
EPS
3.56
P/E Ratio
34.45 $
Value Trade
947.57 M
SEC Financials
Q1 2026Dilution Risk
Revenue
16.29 B
R&D Expenses
12.59 B
Operating CF
3.92 B
Total Assets
128.69 B
Total Liabilities
128.69 B
Equity
45.88 B
D/E Ratio
12,345
7.47 %
Week
8.71 %
1 Month
-0.19 %
3 Month
28.2 %
6 Month
60.61 %
5 Year
8,098.03 %
All Time
Cash Data
Cash Position
5.70 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 4, 2026
Overview
Volume
4.65 M
52 Week Range
75.40 - 125.14
% held by Insiders
0.18 %
% held by Institutions
82.25 %
Enterprise Value
345.73 B
Total Shares
2.48 B
Short %
1.23 %
Float Shares
2.44 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Merck & Company, Inc.
386Total events
9Upcoming
242Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 9
Aug 17, 2026
T1PDUFA Date
PDUFA date set for KEYTRUDA QLEX plus Padcev sBLA in cisplatin-eligible MIBC
TBD
T2Other Regulator Milestone
Planned regulatory submissions outside the US for WELIREG plus LENVIMA
TBD
T1FDA Approval
Enlicitide decanoate to be included in direct-to-patient program following FDA approval
Event history 377
Jun 29, 2026
▲Partnership / LicenseCorporate
New agreement with ADAP Crisis Task Force to improve access and care for people living with HIV
HIVsource ↗
Jun 25, 2026
▲FDA ApprovalPembrolizumabDiscontinuedFDA Decision
FDA approves KEYTRUDA with Trodelvy as first-line treatment for PD-L1+ advanced TNBC
PD-L1+ (CPS ≥10) advanced triple-negative breast cancer (TNBC)source ↗
Jun 25, 2026
▲FDA ApprovalPembrolizumabDiscontinuedFDA Decision
FDA approves KEYTRUDA QLEX with Trodelvy as first-line treatment for PD-L1+ advanced TNBC
PD-L1+ (CPS ≥10) advanced triple-negative breast cancer (TNBC)source ↗
Jun 24, 2026
▲EU ApprovalPembrolizumabDiscontinuedEx-US Regulatory
European Commission approves KEYTRUDA plus Padcev for cisplatin-ineligible resectable MIBC
cisplatin-ineligible resectable muscle-invasive bladder cancersource ↗
Jun 24, 2026
▲EU ApprovalPadcevEx-US Regulatory
European Commission approves Padcev plus KEYTRUDA for cisplatin-ineligible resectable MIBC
cisplatin-ineligible resectable muscle-invasive bladder cancersource ↗
Jun 23, 2026
▲Partnership / LicenseCorporate
Merck KGaA collaborates with Versant Ventures to launch Saturnus Bio
rare genetic cardiomyopathiessource ↗
Jun 22, 2026
▲Primary Endpoint MetTulisokibartClinical Data
Tulisokibart met primary and key secondary endpoints in Phase 3 ATLAS-UC induction-only study
moderately to severely active ulcerative colitissource ↗
Jun 20, 2026
◆PDUFA DatePembrolizumabDiscontinuedRegulatory Filing
PDUFA date set for KEYTRUDA with Padcev for cisplatin-eligible MIBC
muscle-invasive bladder cancersource ↗
Jun 20, 2026
◆PDUFA DatePembrolizumabDiscontinuedRegulatory Filing
PDUFA date set for KEYTRUDA QLEX with Padcev for cisplatin-eligible MIBC
muscle-invasive bladder cancersource ↗
Jun 19, 2026
◆PDUFA DateWELIREGRegulatory Filing
PDUFA date set for WELIREG sNDA and KEYTRUDA/KEYTRUDA QLEX sBLAs
adjuvant treatment of RCC with clear cell componentsource ↗
Jun 19, 2026
◆PDUFA DatePembrolizumabDiscontinuedRegulatory Filing
PDUFA date for KEYTRUDA and KEYTRUDA QLEX sBLAs
adjuvant treatment of RCC with clear cell componentsource ↗
Jun 16, 2026
▲Partnership / LicenseCorporate
Protillion Biosciences announces drug discovery collaboration with Merck
Drug Pipeline Intelligence
A93
Pipeline Score $178.7B
Pipeline ValueFair Value
Valuation Signal637
Drugs Scored2.0x
rNPV / MCap Top 100%
Large Pharma (rank 1 of 905)
Percentile RankMerck & Company, Inc. earns an A-grade pipeline score (93/100), with $178.7B risk-adjusted pipeline value, led by Ipragliflozin in Type 2 Diabetes Mellitus (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omarigliptin Small molecule | Diabetes Mellitus | Phase 3 | NCT01814748 | 53% | $13.6B | COMPLETED | 203 | - | - | Sep 14, 2015 | - | Sep 10, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
KEYTRUDA | bladder cancer | — | 2026-02-12 | |||
KEYTRUDA | bladder cancer | — | 2026-02-12 | |||
KEYTRUDA | bladder cancer | — | 2026-02-12 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MRK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Merck & Company, Inc. (MRK) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
MRK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MRK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MRK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MRK Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MRK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MRKMerck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
Merck is scheduled to hold a conference call on August 4, 2026, to discuss its second-quarter sales and earnings. This call will provide insights into the company's financial performance during that period. Further details about the agenda and participants are yet to be disclosed.
Read more →MRKMerck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
Merck has announced a new agreement with the ADAP Crisis Task Force to enhance access and care for individuals living with HIV. This partnership aims to address critical healthcare needs and improve overall health outcomes for patients. The initiative reflects Merck's dedication to supporting public health initiatives.
Read more →MRKFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
The FDA has approved KEYTRUDA and KEYTRUDA QLEX for use in combination with Trodelvy as a first-line treatment for patients with PD-L1+ advanced triple-negative breast cancer. This approval marks a significant advancement in treatment options for this challenging cancer type, offering new hope to patients and healthcare providers alike.
Read more →MRKEuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
The European Commission has approved the combination of KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer. This marks the first regimen of its kind, combining a PD-1 inhibitor with an antibody-drug conjugate. This approval provides a new treatment avenue for patients who are typically difficult to treat.
Read more →MRKMerck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets
Merck has announced a partnership with Mae to expand the doula workforce in the U.S. This initiative aims to address maternal health disparities, particularly in high-risk markets. The collaboration seeks to improve maternal health outcomes through increased support and resources for expectant mothers.
Read more →MRKMerck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
Merck KGaA has partnered with Versant Ventures to establish Saturnus Bio, a new company focused on developing therapies for rare genetic cardiomyopathies. This collaboration highlights a commitment to addressing unmet medical needs in this area. The initiative aims to leverage innovative approaches to improve patient outcomes.
Read more →MRKMerck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
Merck has partnered with Versant Ventures to establish Saturnus Bio, focusing on developing treatments for rare genetic cardiomyopathies. This collaboration highlights the commitment to addressing significant medical needs in this area. The initiative aims to leverage innovative approaches to improve patient outcomes.
Read more →MRKMerck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Merck's Tulisokibart has met its primary and key secondary endpoints in the Phase 3 ATLAS-UC study focused on patients with moderately to severely active ulcerative colitis. This development marks a significant milestone in the treatment of this condition. Further details on the implications of these results were not provided.
Read more →MRKCystic Fibrosis: Merck Manuals Shares What Patients and Parents Need to Know
Merck Manuals has released an editorial by Dr. Gregory Sawicki on cystic fibrosis, highlighting its genetic nature and the importance of screening for carriers and newborns. While there is no cure, recent advancements in treatments, particularly CFTR modulators, have improved patient outcomes. The article emphasizes the need for multidisciplinary care in managing the disease.
Read more →MRKStudy Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
A recent study highlights the difficulties faced by dog owners and veterinarians in managing allergic skin disease in dogs. The findings emphasize the necessity for a rapid onset treatment suitable for dogs of all ages, indicating a gap in the current treatment landscape. This underscores the urgency for advancements in veterinary dermatological therapies.
Read more →MRKJetstream Venture Fund Secures Position in Rejuvenate Bio, Investing Alongside Industry Giant Merck
Jetstream Venture Fund has announced its investment in Rejuvenate Bio, aligning with major players like Merck Animal Health. This move aims to democratize access to venture capital for retail investors. Rejuvenate Bio focuses on innovative gene therapies for chronic conditions, showcasing a promising pipeline that includes treatments for heart failure and metabolic diseases.
Read more →MRKProtillion Biosciences Announces Drug Discovery Collaboration with Merck
Protillion Biosciences has announced a collaboration with Merck focused on drug discovery. This partnership aims to leverage Protillion's technology to enhance the drug development process. Further details about the specific goals and expected outcomes of the collaboration have not been disclosed.
Read more →MRKLifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
Rejuvenate Bio has successfully closed a $6 million financing round and announced a strategic R&D collaboration with Merck Animal Health. The funds will advance their gene therapy programs targeting chronic and age-related diseases in companion animals. This partnership highlights confidence in Rejuvenate Bio's innovative approach to improving healthspan in both animals and humans.
Read more →MRKMerck Animal Health to Acquire TARGAN
Merck Animal Health has announced its intention to acquire TARGAN. This acquisition aims to enhance Merck's portfolio in the animal health sector. Further details regarding the transaction and its implications have not been disclosed.
Read more →MRKRejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health
Rejuvenate Bio has announced a $6 million financing round alongside a strategic R&D collaboration with Merck Animal Health. This partnership aims to enhance research and development efforts in the field of animal health. The collaboration signifies a positive step towards innovation and growth for both companies.
Read more →MRKMerck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Merck and Gilead have provided an update on the Phase 3 KEYNOTE-D46/EVOKE-03 study. However, the article lacks specific details regarding the findings or implications of this update. Further information may be necessary to understand the impact of this study on the biopharma landscape.
Read more →MRKFDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
The FDA has granted Breakthrough Therapy Designation to Calderasib (MK-1084), an investigational KRAS G12C inhibitor. This designation is specifically for patients with newly diagnosed metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC). This status aims to expedite the development and review of Calderasib, highlighting its potential benefits for patients.
Read more →MRKMerck to Participate in the Jefferies Global Healthcare Conference 2026
Merck announced that Dr. Marjorie Green will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. This event will allow investors, analysts, and the public to listen to a live audio webcast of the presentation. Merck emphasizes its dedication to innovative health solutions and responsible operations.
Read more →MRKMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
Merck has received a favorable opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding the use of KEYTRUDA in combination with Padcev for treating adults with cisplatin-ineligible resectable muscle-invasive bladder cancer. This combination therapy is designed to improve outcomes for patients who have limited treatment options.
Read more →MRKNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
SureNano Science is developing GEP-44, a next-generation GLP-1 therapy aimed at improving metabolic health. The global market for GLP-1 therapies is rapidly expanding, with projections reaching $190 billion by 2035. GEP-44's unique triple agonist mechanism may enhance efficacy and tolerability compared to existing treatments. The company is also exploring innovative drug-delivery methods to improve patient adherence.
Read more →MRKMerck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
Merck presented new long-term data and advancements in its oncology portfolio and pipeline research at the ASCO 2026 conference. The company highlighted its ongoing commitment to cancer research and development. Specific details regarding the data or advancements were not disclosed in the article.
Read more →MRKMerck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
Merck scientists have published a significant paper detailing a new method for the large-scale biocatalytic synthesis of the investigational oral PCSK9 inhibitor, Enlicitide Decanoate. This research could have implications for the treatment of cholesterol-related conditions. The publication highlights advancements in biocatalytic processes, although specific outcomes or applications were not discussed.
Read more →MRKMerck Completes Acquisition of Terns Pharmaceuticals, Inc.
Merck has successfully acquired Terns Pharmaceuticals, enhancing its focus on innovative treatments. The acquisition includes TERN-701, a promising therapy for chronic myeloid leukemia, which has received Breakthrough Therapy Designation from the FDA. This strategic move is expected to impact Merck's financials significantly, with a charge of approximately $5.8 billion anticipated.
Read more →MRKMerck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones Sales Growth Driven by Continued Strength in Oncology
Merck & Co., Inc. reported its first-quarter 2026 financial results showcasing a 5% increase in sales compared to the previous year. The company highlighted important developments, including FDA approval of IDVYNSO and a strategic acquisition aimed at diversifying its portfolio. Despite strong performance in oncology and animal health, Merck faced notable losses per share attributed to acquisition costs and experienced declines in sales for some key products. The CEO expressed optimism about the upcoming Phase 3 data readouts and the overall direction of the pipeline.
Read more →MRKMerck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke
Merck has launched the Playing with Heart program in collaboration with nine professional baseball teams and former players. This initiative aims to educate adults about the significance of monitoring low-density lipoprotein cholesterol (LDL-C), often referred to as 'bad' cholesterol, and its association with heart attack and stroke risks. The program seeks to leverage the popularity of baseball to promote health awareness.
Read more →MRKMerck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Merck has announced the expiration of the Hart-Scott-Rodino waiting period for its acquisition of Terns Pharmaceuticals. This milestone allows Merck to proceed with its cash tender offer of $53.00 per share for Terns' outstanding stock. The completion of the acquisition is still subject to additional conditions, including shareholder participation.
Read more →MRKMerck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
Merck has announced a significant partnership with Google Cloud to enhance its AI capabilities across various functions, including R&D and manufacturing. This collaboration, valued at up to $1 billion, aims to deploy advanced AI solutions to improve productivity and accelerate drug development. The partnership is expected to create a transformative agentic ecosystem that integrates technology with human expertise.
Read more →MRKFDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)
Merck has received FDA approval for IDVYNSO™, a new single-tablet regimen combining doravirine and islatravir for treating HIV-1 infection. This regimen is intended for adults who are already virologically suppressed on a stable antiretroviral regimen. The approval marks a significant advancement in HIV treatment options.
Read more →MRKFDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
The FDA has granted priority review for two supplemental applications for KEYTRUDA and KEYTRUDA QLEX, both in combination with Padcev, aimed at treating muscle-invasive bladder cancer (MIBC) patients eligible for cisplatin. The applications are supported by promising Phase 3 trial results indicating improved survival outcomes. If approved, these treatments could set new standards for perioperative care in MIBC.
Read more →MRKIfinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Daiichi Sankyo and Merck's Biologics License Application for ifinatamab deruxtecan has been accepted for Priority Review by the FDA. This investigational drug targets adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. The application is supported by clinical trial results and aims to provide new treatment options for this difficult-to-treat cancer.
Read more →MRKMerck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
Merck has initiated a tender offer to acquire Terns Pharmaceuticals, Inc. This strategic move is part of Merck's ongoing efforts to expand its portfolio and enhance its capabilities in the biopharmaceutical sector. The acquisition reflects Merck's commitment to growth through strategic partnerships and investments.
Read more →MRKEuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
The European Commission has approved KEYTRUDA (pembrolizumab) in combination with paclitaxel ± bevacizumab for adults with PD-L1 (CPS ≥1) platinum-resistant recurrent ovarian carcinoma. This approval provides a new treatment option for patients who have undergone one or two prior systemic treatments. The combination therapy aims to improve outcomes for this specific patient group.
Read more →MRKMerck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
Merck has announced the initiation of a pivotal Phase 2b/3 trial for MK-8748, a bispecific Tie2 agonist and VEGF inhibitor. This investigational treatment aims to address neovascular age-related macular degeneration. The trial's outcomes could significantly impact the treatment landscape for this condition.
Read more →MRKPositive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Merck's WINREVAIR (sotatercept-csrk) demonstrated significant efficacy in the Phase 2 CADENCE trial, achieving its primary endpoint of reducing pulmonary vascular resistance in adults with combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction. The results support advancing to a registrational Phase 3 study, aiming to provide a treatment option for this underdiagnosed condition. Secondary endpoints also showed promising trends, reinforcing the drug's potential benefits.
Read more →MRKMerck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Merck has announced its acquisition of Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion. This acquisition aims to enhance Merck's hematology pipeline with TERN-701, a novel treatment for chronic myeloid leukemia currently in Phase 1/2 trials. The deal is expected to close in the second quarter of 2026, pending regulatory and shareholder approvals.
Read more →MRKMerck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
Merck will present new data on the long-term efficacy of its HPV vaccines, GARDASIL 9 and GARDASIL, at the EUROGIN International Multidisciplinary HPV Congress 2026. The data shows vaccine effectiveness lasting up to 18 years after administration. This presentation underscores the importance of HPV vaccination in preventing related cancers and diseases.
Read more →MRKMerck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
Merck announced new clinical data from its cardio-pulmonary pipeline to be presented at ACC.26. The data includes positive results from the Phase 3 CORALreef AddOn trial of enlicitide and the Phase 2 CADENCE trial of WINREVAIR. These findings underline Merck's dedication to addressing cardiovascular diseases, particularly hypercholesterolemia and CpcPH-HFpEF.
Read more →MRKKEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
Merck announced positive results from the Phase 3 LITESPARK-022 trial, showing that the combination of KEYTRUDA and WELIREG significantly reduced the risk of disease recurrence or death in earlier-stage renal cell carcinoma patients. The U.S. FDA has accepted supplemental applications for this combination therapy for priority review. This trial marks a significant advancement in the treatment of renal cell carcinoma, potentially reshaping clinical practice.
Read more →MRKWELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Merck and Eisai announced positive results from the Phase 3 LITESPARK-011 trial, showing that the combination of WELIREG (belzutifan) and LENVIMA (lenvatinib) reduced the risk of disease progression or death by 30% compared to cabozantinib in previously treated advanced renal cell carcinoma patients. The FDA has accepted two supplemental New Drug Applications for this combination therapy, with a target action date of October 4, 2026. The trial also reported a significant objective response rate of 52.6%.
Read more →MRKKEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Merck announced positive results from the Phase 3 KEYNOTE-B96 trial, showing that KEYTRUDA, in combination with paclitaxel with or without bevacizumab, significantly improves overall survival for patients with platinum-resistant recurrent ovarian cancer. The treatment reduced the risk of death by 18% compared to standard care. These findings will be presented at the ESGO 2026 Congress, highlighting Merck's commitment to addressing unmet needs in women's cancers.
Read more →MRKKEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
Merck announced that the combination of KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) significantly improves outcomes for patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. The therapy reduced event-free survival events by 47% and the risk of death by 35% compared to traditional neoadjuvant chemotherapy. These findings will be presented at the 2026 ASCO GU Cancers Symposium.
Read more →MRKFDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
Merck Animal Health has received FDA approval for NUMELVI™ (atinvicitinib tablets), the first second-generation JAK inhibitor for managing pruritus associated with allergic dermatitis in dogs aged six months and older. The product will be available in veterinary clinics by spring 2026. NUMELVI aims to enhance the health and comfort of dogs while offering convenience for veterinary practices.
Read more →MRKMerck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
Merck presented late-breaking data from three Phase 3 trials at CROI 2026, showcasing the efficacy and safety of the investigational two-drug regimen doravirine/islatravir (DOR/ISL) for HIV-1 treatment. DOR/ISL showed non-inferiority to the standard treatment BIC/FTC/TAF at Week 48 and maintained virologic suppression at Week 96. The findings suggest DOR/ISL could provide a new treatment option for adults living with HIV-1.
Read more →MRKMerck to Participate in the TD Cowen 46th Annual Health Care Conference
Merck announced that executives Caroline Litchfield and Dr. Dean Y. Li will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The event will be accessible via a live audio webcast for investors, analysts, and the public. Merck continues to focus on its mission to improve global health through innovative research.
Read more →MRKMerck Evolves Human Health Operating Structure to Support Portfolio Execution
Merck is restructuring its Human Health organization to enhance commercial execution across various therapeutic areas. This includes establishing an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. New appointments, including Jannie Oosthuizen and Brian Foard, aim to leverage their expertise for strategic growth. The company is also advancing a robust pipeline with numerous Phase 3 studies underway.
Read more →MRKMerck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
Merck and Mayo Clinic have announced a strategic collaboration to enhance drug discovery through artificial intelligence and advanced analytics. This partnership will integrate Mayo Clinic's clinical insights and genomic data with Merck's AI capabilities. The collaboration aims to focus on high-need therapeutic areas, potentially speeding up the development of effective therapies.
Read more →MRKMerck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
Merck announced the presentation of new data on genitourinary cancers at the 2026 ASCO GU Cancers Symposium. The studies will include findings on muscle invasive bladder cancer and renal cell carcinoma, showcasing Merck's commitment to improving patient outcomes. Key data will feature results from their cancer medicines, including KEYTRUDA, WELIREG, and LENVIMA, as well as an investigational ADC. This underscores Merck's leadership in the oncology field.
Read more →MRKKEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
Merck has received FDA approval for KEYTRUDA and KEYTRUDA QLEX, which are now indicated for adults with PD-L1+ platinum-resistant ovarian cancer. The approvals are based on the Phase 3 KEYNOTE-B96 trial, demonstrating significant improvements in progression-free and overall survival compared to placebo. This marks a notable advancement in treatment options for patients facing limited choices due to platinum resistance.
Read more →MRKMerck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants
Merck has received Health Canada approval for ENFLONSIA® (clesrovimab) to prevent respiratory syncytial virus (RSV) in newborns and infants. This monoclonal antibody offers protection during the RSV season and is supported by positive results from the CLEVER and SMART clinical trials. The approval enhances RSV prevention strategies for vulnerable infants across Canada.
Read more →MRKMerck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
Merck & Co., Inc. reported strong financial results for Q4 and full year 2025, with a notable increase in EPS and sales driven by oncology products like KEYTRUDA. The company also highlighted progress in its pipeline, including positive results from Phase 3 trials. However, challenges included a decline in gross margin and lower sales in the vaccines sector.
Read more →MRKMerck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results ; Highlights Progress Advancing Broad, Diverse Pipeline Reports Strength in Oncology and Animal Health, Plus
Merck & Co., Inc. announced its financial results for the fourth quarter and full year of 2025, showing a modest increase in worldwide sales of 1% year-over-year, amounting to $65 billion. The company highlighted significant growth in its oncology and animal health segments, alongside positive outcomes from numerous late-stage trials. However, GAAP earnings per share experienced a noteworthy decline, reflecting the impact of recent acquisitions and business transactions. Despite these challenges, Merck's diverse pipeline and new product launches contributed positively to its overall performance.
Read more →MRKMerck Announces Second-Quarter 2026 Dividend
Merck has announced a quarterly dividend of $0.85 per share for the second quarter of 2026. This dividend will be paid on April 7, 2026, to shareholders recorded by March 16, 2026. The announcement underscores Merck's commitment to returning value to its shareholders while continuing its mission in biopharmaceutical research and development.
Read more →MRKMerck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Merck (MRK) announced that its CEO Robert M. Davis and EVP Dr. Dean Y. Li will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The event will be accessible via a live audio webcast, inviting investors, analysts, and the public to listen. This participation underscores Merck's ongoing commitment to advancing healthcare solutions.
Read more →MRKMerck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
Merck has announced a significant agreement with the U.S. government to enhance access to its medicines and reduce costs for American patients. This includes a direct-to-patient program offering key products at reduced prices. The company is also committing over $70 billion to U.S. manufacturing and innovation, aiming to address disparities in drug pricing. Enlicitide, a potential oral PCSK9 inhibitor, is expected to be part of this initiative pending FDA approval.
Read more →MRKMerck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
Merck announced plans to present first-in-human data for Alzheimer's candidates MK-2214 and MK-1167 at CTAD 2025. MK-2214 has received Fast Track Designation from the FDA, aimed at expediting its development for Alzheimer's treatment. The company emphasizes its commitment to addressing the challenges of Alzheimer's disease through innovative research.
Read more →MRKMerck to Participate in the Citi 2025 Global Healthcare Conference
Merck announced its participation in the Citi 2025 Global Healthcare Conference, scheduled for December 3, 2025. Chirfi Guindo and Dr. Eliav Barr will represent the company in a fireside chat. Investors and the public can access a live audio webcast of the event. Merck emphasizes its commitment to advancing health solutions.
Read more →MRKMerck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
Merck announced its participation in the 8th Annual Evercore ISI HealthCONx Conference, scheduled for December 2, 2025. Key executives, including Chirfi Guindo and Dr. Eliav Barr, will engage in a fireside chat. The event will be accessible to investors, analysts, and the public via a live audio webcast.
Read more →MRKMerck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
Merck will present new data at the ASH 2025 Annual Meeting, showcasing advancements in its hematology pipeline. The company is highlighting over 20 abstracts, including results from studies on MK-1045, bomedemstat, and nemtabrutinib. These presentations emphasize Merck's commitment to addressing significant unmet needs in hematologic malignancies.
Read more →MRKMerck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results - Total Worldwide Sales Were $17.3 Billion, an Increase of 4% From Third Quarter 2024; Excluding the Impact of Foreign
Merck & Co., Inc. reported a strong third quarter for 2025, with worldwide sales reaching $17.3 billion, a 4% increase from the previous year. The company achieved significant profits, with a GAAP net income of $5.8 billion and a notable earnings per share rise of 87%. Performance drivers included robust demand for their major product, KEYTRUDA, although some areas like vaccine sales experienced declines. Merck emphasized ongoing investments in their pipeline and strategic acquisitions to sustain growth.
Read more →MRKMerck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results - Total Worldwide Sales Were $15.8 Billion, a Decrease of 2% From Second Quarter 2024 Both Nominally and Excluding the
Merck & Co., Inc. reported second-quarter 2025 financial results, revealing total sales of $15.8 billion, a 2% decline from the same quarter in 2024. The company announced an acquisition of Verona Pharma to strengthen its portfolio and a multiyear optimization initiative aimed at redirecting investments towards new growth drivers. Despite some product successes, including KEYTRUDA, overall sales saw declines, particularly in their vaccine segment. The net income for the quarter also fell by 19%, reflecting some financial pressure on the company.
Read more →MRKMerck Announces First-Quarter 2025 Financial Results - Total Worldwide Sales Were $15.5 Billion, a Decrease of 2% From First Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 1% KEYTRUDA Sal
Merck (MRK) reported its financial results for Q1 2025, highlighting total worldwide sales of $15.5 billion, a slight decline of 2% compared to Q1 2024. KEYTRUDA sales increased by 4%, while GARDASIL sales saw a significant drop of 41%. The company continues to anticipate strong sales growth and has revised its non-GAAP EPS outlook due to a one-time charge related to a license agreement. Overall, Merck remains focused on advancing its product pipeline amid ongoing financial challenges.
Read more →MRKMerck Announces Fourth-Quarter and Full-Year 2024 Financial Results - Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange,
Merck announced its financial results for the fourth quarter and full year of 2024, reporting a 7% increase in worldwide sales to $15.6 billion. The strong growth was attributed to the popularity of its innovative portfolio, particularly the cancer drug KEYTRUDA. However, some products like GARDASIL and JANUVIA faced decreased demand, impacting overall performance. The company continues to progress on clinical programs and business development while managing the challenges posed by generic competition and market variations.
Read more →MRKSurendralal Karsanbhai Elected to Merck Board of Directors RAHWAY, N.J.
Merck has announced the election of Surendralal Karsanbhai to its Board of Directors, effective January 1, 2025. Karsanbhai, who has served as the CEO of Emerson Electric Co., will stand for election by shareholders in May 2025. His extensive experience and global perspective are expected to enhance Merck's leadership. With this addition, the Merck board will consist of 13 members, continuing the company's commitment to strategic governance.
Read more →MRKMerck Announces Third-Quarter 2024 Financial Results - Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 7% o KEYTRUDA
Merck reported its third-quarter financial results for 2024, showcasing total worldwide sales of $16.7 billion, representing a 4% increase from the previous year. The growth was attributed to increased usage of KEYTRUDA and new launches such as WINREVAIR and CAPVAXIVE. However, this positive trend was partially overshadowed by declines in sales for products like JANUVIA and GARDASIL, notably impacted by lower demand in China. The net income also decreased significantly, reflecting the challenges faced in the market amidst robust competition and pricing pressures.
Read more →MRKMerck Announces Second-Quarter 2024 Financial Results - Total Worldwide Sales Were $16.1 Billion, an Increase of 7% From Second Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 11% - KEYTRU
Merck (MRK) reported its financial results for Q2 2024, revealing total sales of $16.1 billion, a 7% increase from Q2 2023. The surge was primarily driven by strong performance in oncology and vaccines, particularly for KEYTRUDA, which grew 16%. However, the company also noted declines in some product lines due to market competition and pricing pressures. Despite these challenges, Merck highlighted its solid operational execution and the successful launch of WINREVAIR as indicators of ongoing business momentum.
Read more →MRKMerck Announces First-Quarter 2024 Financial Results - Sales Reflect Continued Strong Growth in Oncology and Vaccines - Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Ex
Merck reported strong financial results for the first quarter of 2024, achieving $15.8 billion in sales, marking a 9% increase from the previous year. Key drivers of this growth included increased global uptake of the oncology drug KEYTRUDA and strong vaccine sales, particularly GARDASIL. The company also announced the launch of WINREVAIR targeting pulmonary arterial hypertension, indicating a commitment to innovation and expanding their product lineup. Net income and earnings per share saw substantial increases, reflecting effective cost management and an improved product mix.
Read more →MRKMerck Announces Fourth-Quarter and Full-Year 2023 Financial Results - Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines - Fourth-Quarter Worldwide Sales Were $14.6 Bill
Merck reported its fourth-quarter and full-year financial results for 2023, highlighting substantial growth in oncology and vaccine sales that underpinned total sales of $14.6 billion for Q4. The company's initiatives reached over 500 million patients worldwide, with a significant investment of approximately $30 billion in research and development. However, the report also revealed a GAAP net loss per share of $0.48 in the fourth quarter, primarily due to strategic collaborations and a 77% decline in sales of the COVID-19 treatment LAGEVRIO, which has raised concerns over future revenue streams.
Read more →MRKMerck Announces Third-Quarter 2023 Financial Results - Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2
Merck reported robust financial results for the third quarter of 2023, with total worldwide sales reaching $16.0 billion—a 7% increase from the same period last year. The growth was largely driven by its oncology and vaccine segments, despite some challenges such as generic competition affecting specific products like JANUVIA. The company also highlighted strong gains in GAAP net income, which increased by 46% year-over-year, underscoring operational strength and strategic investments in its pipeline. However, foreign exchange pressures and part of their business showing declines pose some ongoing challenges.
Read more →MRKMerck Announces Second-Quarter 2023 Financial Results - Sales Reflect Sustained Underlying Growth, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $15.0 Billion, an Increase of 3% From Sec
Merck (MRK) reported its second-quarter 2023 financial results, highlighting a total sales increase of 3% to $15.0 billion. The growth was driven mainly by strong performances in oncology and vaccines, particularly with products like KEYTRUDA and GARDASIL. However, the company experienced significant losses per share attributed to the acquisition of Prometheus Biosciences, as well as declining sales of LAGEVRIO. Despite these challenges, Merck remains optimistic about its future prospects and pipeline development.
Read more →MRKMerck Announces First-Quarter 2023 Financial Results - First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines - Total Worldwide
Merck (MRK) reported its financial results for the first quarter of 2023, highlighting a 9% decline in total sales to $14.5 billion. Significant contributions came from the oncology segment, with KEYTRUDA experiencing a 20% increase in sales. However, the overall performance was impacted by a substantial drop in sales of the COVID-19 treatment LAGEVRIO, which fell by 88%. Despite these challenges, Merck is focused on continuing growth in key areas such as oncology and vaccines, as reflected in their business strategy.
Read more →MRKMerck Announces Fourth-Quarter and Full-Year 2022 Financial Results - Fourth-Quarter and Full-Year 2022 Results Reflect Sustained Strong Revenue Growth - Fourth-Quarter 2022 Worldwide S
Merck has announced its fourth-quarter and full-year 2022 financial results, showcasing significant revenue growth. The company’s total sales reached $59.3 billion for the year, up 22% from 2021, driven primarily by the performance of oncology products, notably KEYTRUDA. Despite these achievements, the company reported a decrease in GAAP net income and several product sales, highlighting challenges in specific segments. Merck’s CEO emphasized the ongoing innovation and value creation projected for its products moving forward.
Read more →MRKMerck Announces Third-Quarter 2022 Financial Results
FOR IMMEDIATE RELEASE Merck Announces Third-Quarter 2022 Financial Results RAHWAY, N.J., Oct. 27, 2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2022. "We continue to execute on our strate
Read more →MRKMerck Announces Second-Quarter 2022 Financial Results - Merck Delivers Robust Sales Growth and Important Clinical Advancements in Second Quarter - Second-Quarter 2022 Worldwide Sales Were $14.6 Billion, an I
Merck Announces Second-Quarter 2022 Financial Results RAHWAY, N.J., July 28, 2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2022. "I continue to be immensely proud of how the Merck team is
Read more →MRKMelissa Moody Investor Contacts: Peter Dannenbaum (215) 407-3536 (908) 740-1037 Johanna Herrmann (617) 216-6029 Steven Graziano (908) 740-6582 Merck Announces First-Quarter 2022 Financial Res
Merck Announces First-Quarter 2022 Financial Results KENILWORTH, N.J., April 28, 2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2022. "We successfully delivered across our key strategic pri
Read more →MRKMERCK & CO., INC. 2021 QUARTERLY AND ANNUAL GAAP TO NON-GAAP RECONCILIATIONS - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) In 2022, the Company will be changing the treatment of cert
MERCK & CO., INC. 2021 QUARTERLY AND ANNUAL GAAP TO NON-GAAP RECONCILIATIONS - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) In 2022, the Company will be changing the treatment of certain items for purposes of its non-GAAP reporting. Historical
Read more →MRKMelissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Johanna Herrmann (617) 216-6029 Steven Graziano (908) 740-6582 Merck Announces Fourth-Quarter and Full-Year 202
Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results KENILWORTH, N.J., Feb. 3, 2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2021. "Our business achieved stro
Read more →MRKPatrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Melissa Moody Raychel Kruper (215) 407-3536 (908) 740-2107 Merck Announces Third-Quarter 2021 Financial
FOR IMMEDIATE RELEASE Merck Announces Third-Quarter 2021 Financial Results KENILWORTH, N.J., Oct. 28, 2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2021. "Merck delivered another strong q
Read more →MRKPatrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Melissa Moody (215) 407-3536 Raychel Kruper (908) 740-2107 Leslie A. Brun Resigns from Mer
Media Contacts: Patrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Melissa Moody (215) 407-3536 Raychel Kruper (908) 740-2107 Leslie A. Brun Resigns from Merck Board of Directors KENILWORTH, N.J., Aug. 20, 2021 - Merck (NYSE: MRK), known as MSD o
Read more →MRKPatrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Melissa Moody (215) 407-3536 Raychel Kruper (908) 740-2107 Merck Announces Second-Quarter 2021 Financia
FOR IMMEDIATE RELEASE Merck Announces Second-Quarter 2021 Financial Results KENILWORTH, N.J., July 29, 2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2021. "We are encouraged by the stron
Read more →MRKMERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) On
(1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. Income from discontinued operations was also compute
Read more →MRKMerck Announces First-Quarter 2021 Financial Results
FOR IMMEDIATE RELEASE Merck Announces First-Quarter 2021 Financial Results KENILWORTH, N.J., April 29, 2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2021. "While our results this quarter
Read more →MRKPatrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Michael DeCarbo (908) 740-1807 Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Succes
Media Contacts: Patrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Michael DeCarbo (908) 740-1807 Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman KENILWORTH, N.J
Read more →MRKPatrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Michael DeCarbo (908) 740-1807 Merck Announces Fourth-Quarter and Full-Year 2020 Financial
FOR IMMEDIATE RELEASE Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results KENILWORTH, N.J., Feb. 4, 2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2020. "Des
Read more →MRKPatrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Michael DeCarbo (908) 740-1807 Dr. Stephen Mayo Elected to Merck Board of Directors KENILWO
FOR IMMEDIATE RELEASE Dr. Stephen Mayo Elected to Merck Board of Directors KENILWORTH, N.J., Feb. 1, 2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Stephen "Steve" L. Mayo, professor, California Institute of Technology, wil
Read more →MRKPamela Eisele Investor Contacts: Peter Dannenbaum (267) 305-3558 (908) 740-1037 Patrick Ryan Michael DeCarbo (201) 452-2409 (908) 740-1807 Merck Announces Third-Quarter
FOR IMMEDIATE RELEASE Merck Announces Third-Quarter 2020 Financial Results KENILWORTH, N.J., Oct. 27, 2020 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2020. "We continue to execute on our st
Read more →MRKPamela Eisele Investor Contacts: Peter Dannenbaum (267) 305-3558 (908) 740-1037 Patrick Ryan Michael DeCarbo (201) 452-2409 (908) 740-1807 Merck Announces Second-Quarter
FOR IMMEDIATE RELEASE Merck Announces Second-Quarter 2020 Financial Results KENILWORTH, N.J., July 31, 2020 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2020. "Despite the impact COVID-19 ha
Read more →MRKJennifer Mauer Investor Contacts: Peter Dannenbaum (908) 740-1801 (908) 740-1037 Pamela Eisele Michael DeCarbo (267) 305-3558 (908) 740-1807 Merck Announces First-Quarte
FOR IMMEDIATE RELEASE Merck Announces First-Quarter 2020 Financial Results KENILWORTH, N.J., April 28, 2020 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2020. "In this challenging and unprece
Read more →MRKJennifer Mauer Investor Contacts: Peter Dannenbaum (908) 740-1801 (908) 740-1037 Pamela Eisele Michael DeCarbo (267) 305-3558 (908) 740-1807 Merck Announces Fourth-Quart
FOR IMMEDIATE RELEASE Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results KENILWORTH, N.J., Feb. 5, 2020 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2019. "As
Read more →MRKJennifer Mauer Investor Contact: Peter Dannenbaum (908) 740-1801 (908) 740-1037 Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors KENILWORTH, N.J
FOR IMMEDIATE RELEASE Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors KENILWORTH, N.J., Jan. 31, 2020 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Christine ("Kricket") E. Seidman, professor, Harvard
Read more →MRKJennifer Mauer Investor Contacts: Peter Dannenbaum (908) 740-1801 (908) 740-1037 Pamela Eisele Michael DeCarbo (267) 305-3558 (908) 740-1807 Merck Announces Third-Quarte
Merck Announces Third-Quarter 2019 Financial Results KENILWORTH, N.J., Oct. 29, 2019 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2019. "We achieved another quarter of strong revenue and earni
Read more →MRKJessica Fine Investor Contacts: Teri Loxam (908) 740-1707 (908) 740-1986 Pamela Eisele Michael DeCarbo (267) 305-3558 (908) 740-1807 Merck Announces Second-Quarter 2019
FOR IMMEDIATE RELEASE Merck Announces Second-Quarter 2019 Financial Results Second-Quarter 2019 Worldwide Sales Were $11.8 Billion, an Increase of 12%; Sales Increased 15% Excluding Negative Impact from Foreign Exchange; Growth Driven by Oncology and Human Health Vaccines KEYT
Read more →MRKJennifer Mauer Investor Contacts: Teri Loxam (908) 740-1801 (908) 740-1986 Pamela Eisele Michael DeCarbo (267) 305-3558 (908) 740-1807 Merck Announces First-Quarter 2019
FOR IMMEDIATE RELEASE Merck Announces First-Quarter 2019 Financial Results First-Quarter 2019 Worldwide Sales Were $10.8 Billion, an Increase of 8%; Sales Increased 11% Excluding Negative Impact from Foreign Exchange; Growth Driven by Oncology and Vaccines Sales in China Were
Read more →MRKJennifer Mauer Investor Contacts: Teri Loxam (908) 740-1801 (908) 740-1986 Claire Gillespie Michael DeCarbo (267) 305-0932 (908) 740-1807 Merck Announces Fourth-Quarter
FOR IMMEDIATE RELEASE Merck Announces Fourth-Quarter and Full-Year 2018 Financial Results Fourth-Quarter 2018 Worldwide Sales Were $11.0 Billion, an Increase of 5 Percent, Including a 3 Percent Negative Impact from Foreign Exchange; Full-Year 2018 Worldwide Sales Were $42.3 Bil
Read more →MRKClaire Gillespie Investor Contacts: Teri Loxam (267) 305-0932 (908) 740-1986 Michael DeCarbo (908) 740-1807 Merck Announces Third-Quarter 2018 Financial Results Third-Qua
FOR IMMEDIATE RELEASE Merck Announces Third-Quarter 2018 Financial Results Third-Quarter 2018 Worldwide Sales Were $10.8 Billion Third-Quarter 2018 GAAP EPS was $0.73, Third-Quarter Non-GAAP EPS was $1.19 Company Narrows 2018 Full-Year Revenue Range to be Between $42.1 Billio
Read more →MRKClaire Gillespie (267) 305-0932 Investor Contacts: Teri Loxam (908) 740-1986 Peter Dannenbaum (908) 740-1037 Merck Board Rescinds Mandatory CEO Retirement Policy Current
Merck Board Rescinds Mandatory CEO Retirement Policy Current CEO Kenneth Frazier to Continue in Role KENILWORTH, N.J., Sept. 26, 2018 Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that its Board of Directors has rescinded its policy subje
Read more →MRKTracy Ogden Investor Contacts: Teri Loxam (908) 740-1747 (908) 740-1986 Claire Gillespie (267) 305-0932 Michael DeCarbo (908) 740-1807 Merck Announces Second-Quarter 201
FOR IMMEDIATE RELEASE Merck Announces Second-Quarter 2018 Financial Results Second-Quarter 2018 Worldwide Sales Were $10.5 Billion, an Increase of 5 Percent, Including a 1 Percent Positive Impact from Foreign Exchange Second-Quarter 2018 GAAP EPS was $0.63, Second-Quarter Non-
Read more →MRKTracy Ogden Investor Contacts: Teri Loxam (908) 740-1747 (908) 740-1986 Claire Gillespie (267) 305-0932 Michael DeCarbo (908) 740-1807 Merck Announces First-Quarter 2018
FOR IMMEDIATE RELEASE Merck Announces First-Quarter 2018 Financial Results First-Quarter 2018 Worldwide Sales Were $10.0 Billion, an Increase of 6 Percent, Including a 3 Percent Positive Impact from Foreign Exchange First-Quarter 2018 GAAP EPS was $0.27, Reflecting a $1.4 Bill
Read more →Competitive Position
How MRK ranks across every disease it competes inCompetitive Position is a premium feature
See how MRK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial